Literature DB >> 28300323

Acquired perforating dermatosis: clinicopathological study of 31 cases, emphasizing pathogenesis and treatment.

A J García-Malinis1, E Del Valle Sánchez2, M P Sánchez-Salas3, E Del Prado1, C Coscojuela1, Y Gilaberte1.   

Abstract

BACKGROUND: Acquired perforating dermatosis (APD) is a rare group of skin disorders of unknown aetiology and pathogenesis and is associated with several systemic diseases.
OBJECTIVE: We review the clinicopathological features, associated systemic diseases and treatment response in a series of APD patients.
METHODS: We conducted a retrospective observational study of all patients histologically diagnosed with APD in Hospital San Jorge (Huesca, Spain) between 2002 and 2014. Demographic and clinical features were collected from medical records. Statistical analyses were carried out using SPSS software (version 20.0; IBM Corp, Armonk, NY, USA).
RESULTS: The study population consisted of 31 patients (19 women and 12 men), with a mean age of 54 years. Reactive perforating collagenosis (n = 15, 45%) was the most common histopathologic type. The most frequently affected area was the lower limbs (66.6%, n = 22), and pruritus was present in 19 patients (61.3%, P = 0.005). Arterial hypertension (30.3%) was the most common associated condition. Five patients were receiving treatment with infliximab when diagnosed with APD. Most patients responded to topical steroids and oral antihistamines (n = 15). LIMITATIONS: This study is retrospective, and the sample size is limited.
CONCLUSION: Acquired perforating dermatosis is an underdiagnosed dermatosis frequently associated with systemic disorders. Its pathogenesis may involve vascular damage, not only in patients with diabetes, but also in those with arterial hypertension and chronic venous insufficiency. Control of pruritus and underlying extracutaneous disorders, as well as discontinuation of the treatment with biologics, are important aspects of the management of this dermatosis.
© 2017 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28300323     DOI: 10.1111/jdv.14220

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  5 in total

1.  Doxycycline Combined with NB-UVB Phototherapy for Acquired Reactive Perforating Collagenosis.

Authors:  Limu Gao; Lixiong Gu; Zhen Chen; Shuanglin Cao
Journal:  Ther Clin Risk Manag       Date:  2020-09-24       Impact factor: 2.423

2.  Acquired Reactive Perforating Collagenosis Associated with Linear Immunoglobulin A Bullous Disease.

Authors:  Qi Tan; Li Liu; Jian Zhang; Si-Li Ni
Journal:  Acta Derm Venereol       Date:  2020-09-23       Impact factor: 3.875

3.  Acquired reactive perforating collagenosis in association with prostate adenocarcinoma, chronic lymphocytic leukemia, and Graves' disease.

Authors:  Leyla Huseynova; Neslihan Akdogan; Özay Gököz; Sibel Ersoy Evans
Journal:  An Bras Dermatol       Date:  2020-04-18       Impact factor: 1.896

4.  Dermoscopic pattern of Kyrle's disease.

Authors:  Ozlem Ozbagcivan; Banu Lebe; Emel Fetil
Journal:  An Bras Dermatol       Date:  2020-02-12       Impact factor: 1.896

5.  Successful treatment of acquired reactive perforating collagenosis with itraconazole.

Authors:  Binrong Ye; Yi Cao; Yeqiang Liu
Journal:  Eur J Med Res       Date:  2021-07-13       Impact factor: 2.175

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.